Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common
-
Shares outstanding
-
7,989,235
-
Total 13F shares
-
1,141,975
-
Share change
-
+495,464
-
Total reported value
-
$10,140,752
-
Price per share
-
$8.88
-
Number of holders
-
17
-
Value change
-
+$4,400,866
-
Number of buys
-
10
-
Number of sells
-
3
Institutional Holders of Traws Pharma, Inc. - Common (TRAW) as of Q4 2024
As of 31 Dec 2024,
Traws Pharma, Inc. - Common (TRAW) was held by
17 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,141,975 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, PERCEPTIVE ADVISORS LLC, Alyeska Investment Group, L.P., Ikarian Capital, LLC, Vestal Point Capital, LP, GEODE CAPITAL MANAGEMENT, LLC, MORGAN STANLEY, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, and MILLENNIUM MANAGEMENT LLC.
This page lists
17
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.